Researchers from the USDA have developed a vaccine against African swine fever (ASF) that has the potential to be commercially produced and maintained for vaccination efficacy. The vaccine can protect European and Asian pigs from the current Asian strain of the virus. The vaccine has shown immunity in a third of the animals after two weeks and full protection in all animals by the fourth week. The USDA is planning to commercialize the vaccine with Navetco, a Vietnamese national veterinary society, and is also evaluating other potential business partners for vaccine development. The USDA has developed and patented five experimental ASF vaccines and has entered into seven licenses with pharmaceutical companies for vaccine development.